BIOCRYST PHARMACEUTICALS INC Quarterly Operating Lease, Right-of-Use Asset in USD from Q3 2021 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of lessee's right to use underlying asset under operating lease.
Summary
Biocryst Pharmaceuticals Inc quarterly Operating Lease, Right-of-Use Asset history and growth rate from Q3 2021 to Q3 2024.
  • Biocryst Pharmaceuticals Inc Operating Lease, Right-of-Use Asset for the quarter ending September 30, 2024 was $8.34M, a 26.7% decline year-over-year.
Operating Lease, Right-of-Use Asset, Quarterly (USD)
Operating Lease, Right-of-Use Asset, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date Report Filed
Q3 2024 $8.34M -$3.04M -26.7% Sep 30, 2024 10-Q 2024-11-05
Q2 2024 $8.54M +$1.59M +22.9% Jun 30, 2024 10-Q 2024-08-06
Q1 2024 $8.86M +$1.82M +25.8% Mar 31, 2024 10-Q 2024-05-07
Q4 2023 $8.68M +$4.44M +105% Dec 31, 2023 10-Q 2024-11-05
Q3 2023 $11.4M +$4.58M +67.4% Sep 30, 2023 10-Q 2023-11-08
Q2 2023 $6.95M Jun 30, 2023 10-Q 2023-08-07
Q1 2023 $7.05M Mar 31, 2023 10-Q 2023-05-08
Q4 2022 $4.24M -$2.23M -34.5% Dec 31, 2022 10-K 2024-02-27
Q3 2022 $6.8M +$1.61M +30.9% Sep 30, 2022 10-Q 2022-11-04
Q4 2021 $6.47M Dec 31, 2021 10-K 2023-02-27
Q3 2021 $5.19M Sep 30, 2021 10-Q 2021-11-04
* An asterisk sign (*) next to the value indicates that the value is likely invalid.